These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16729909)

  • 1. Chemotherapy for non-clear-cell renal cell carcinoma.
    David KA; Milowsky MI; Nanus DM
    Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-clear cell advanced kidney cancer: is there a gold standard?
    Sánchez P; Calvo E; Durán I
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy for sarcomatoid renal cell carcinoma.
    Pagliaro LC; Tannir N; Sircar K; Jonasch E
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors.
    Moch H; Gasser T; Amin MB; Torhorst J; Sauter G; Mihatsch MJ
    Cancer; 2000 Aug; 89(3):604-14. PubMed ID: 10931460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
    Tickoo SK; Alden D; Olgac S; Fine SW; Russo P; Kondagunta GV; Motzer RJ; Reuter VE
    J Urol; 2007 Apr; 177(4):1258-63. PubMed ID: 17382701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic non-clear cell renal cell carcinoma: current therapeutic options.
    Schrader AJ; Olbert PJ; Hegele A; Varga Z; Hofmann R
    BJU Int; 2008 Jun; 101(11):1343-5. PubMed ID: 18241246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
    Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
    Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug therapies for advanced renal cell carcinoma.
    Gore ME; Harrison ML; Montes A
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced treatments in non-clear renal cell carcinoma.
    Tazi el M; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
    Urol J; 2011; 8(1):1-11. PubMed ID: 21404194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
    Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
    Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Paule B; Brion N
    Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on novel agents in renal cell carcinoma.
    Tamaskar I; Pili R
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.